Liberum Capital Reconfirms a Hold Rating on Card Factory Plc (LON:CARD) and GBX 240.00 Target; 5 Bullish Analysts Covering Verastem, Inc. (VSTM)

Liberum Capital currently has a GBX 240.00 PT on the 747.11M GBP market cap company or 10.45% upside potential. In analysts note revealed to investors and clients on Tuesday morning, Card Factory Plc (LON:CARD) stock had its Hold Rating reiterated by stock research analysts at Liberum Capital.

Among 10 analysts covering Verastem (NASDAQ:VSTM), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. Verastem has $17 highest and $1.5000 lowest target. $8.31’s average target is 172.46% above currents $3.05 stock price. Verastem had 29 analyst reports since September 9, 2015 according to SRatingsIntel. Raymond James downgraded the shares of VSTM in report on Tuesday, September 29 to “Outperform” rating. As per Wednesday, August 16, the company rating was maintained by Oppenheimer. Oppenheimer maintained Verastem, Inc. (NASDAQ:VSTM) on Monday, June 26 with “Buy” rating. The firm has “Buy” rating given on Friday, June 16 by Oppenheimer. JMP Securities downgraded the stock to “Mkt Perform” rating in Tuesday, September 29 report. Oppenheimer maintained the shares of VSTM in report on Wednesday, July 12 with “Buy” rating. H.C. Wainwright maintained the shares of VSTM in report on Thursday, September 17 with “Buy” rating. The firm has “Overweight” rating given on Wednesday, September 6 by Cantor Fitzgerald. The firm earned “Buy” rating on Tuesday, July 25 by Oppenheimer. Raymond James initiated the stock with “Strong Buy” rating in Wednesday, September 9 report. See Verastem, Inc. (NASDAQ:VSTM) latest ratings:

13/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
11/12/2017 Broker: Raymond James Rating: Buy
30/11/2017 Broker: Roth Capital Rating: Buy New Target: $12.0 Initiate
25/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $17.0 Maintain
06/09/2017 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Upgrade
16/08/2017 Broker: Oppenheimer Rating: Buy Maintain
10/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.5000
08/08/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
25/07/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain

Investors sentiment increased to 1.4 in 2017 Q3. Its up 0.23, from 1.17 in 2017Q2. It is positive, as 6 investors sold Verastem, Inc. shares while 19 reduced holdings. 19 funds opened positions while 16 raised stakes. 12.96 million shares or 49.25% more from 8.68 million shares in 2017Q2 were reported. Artal Gru has invested 0.06% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Thompson Davis & owns 1,200 shares. Moreover, Numeric Invsts Limited Liability Com has 0.01% invested in Verastem, Inc. (NASDAQ:VSTM). Raymond James Fincl Service Advsrs Inc reported 17,830 shares or 0% of all its holdings. 10,000 are owned by Beaumont Partners Limited Company. Vanguard Group stated it has 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Point72 Asset Ltd Partnership stated it has 0.03% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Stifel Fincl holds 0.01% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 370,920 shares. 73,787 are held by Virtu Financial Ltd Liability Corp. Eam Investors Ltd Liability Com invested in 0.28% or 445,017 shares. Bancorp Of America Corp De, a North Carolina-based fund reported 5,011 shares. Alpine Woods Limited Liability Company reported 0.01% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Advisory Ntwk Ltd Llc reported 15,325 shares or 0.01% of all its holdings. State Street owns 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 22,011 shares. Deutsche National Bank Ag stated it has 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM).

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $154.14 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

The stock increased 1.33% or $0.04 during the last trading session, reaching $3.05. About 477,531 shares traded. Verastem, Inc. (NASDAQ:VSTM) has risen 71.53% since January 16, 2017 and is uptrending. It has outperformed by 54.83% the S&P500.

The stock increased 1.58% or GBX 3.3998 during the last trading session, reaching GBX 218.7998. About 242,096 shares traded. Card Factory PLC (LON:CARD) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.